Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...

Viruses, like those that cause COVID-19 or HIV, are formidable opponents once they invade our bodies. Antiviral treatments strive to block a virus or halt its replication. However, viruses are dynamic ...

While the EIS program has likely been spared this time, the fact that its existence was in jeopardy at all highlights the ...

Deutsche Bank upgraded Gilead Sciences (NASDAQ:GILD) on Tuesday, citing the antiviral developer’s HIV treatment franchise, ...

By paralyzing frontline response efforts led by community groups, the US decision to freeze funding is weakening health systems across the Global South. The freeze not only jeopardizes precious gains ...

The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV ...

An HIV drug was named “2024 Breakthrough of the Year” by Science Magazine. Biochemistry research from the University of Utah ...

The largest conference of HIV medical experts and scientists in India this year, the 16th National Conference of AIDS Society ...

Gilead Sciences has won Food and Drug Administration priority review for its proposed lenacapavir twice-yearly shot to prevent HIV. Gilead on Tuesday said an FDA green light would make lenacapavir the ...

From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell ...

Understand how drug use increases HIV risk and learn about prevention strategies that save lives. Medical experts explain ...

Human immunodeficiency virus (HIV) treatment has gotten so good that people can take a pill once a day to achieve viral ...